226 related articles for article (PubMed ID: 24481633)
1. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
[No Abstract] [Full Text] [Related]
2. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Matthaei S
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
[No Abstract] [Full Text] [Related]
3. Canagliflozin: a novel treatment option for type 2 diabetes.
Dietrich E; Powell J; Taylor JR
Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
6. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
[TBL] [Abstract][Full Text] [Related]
7. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Rupprecht H
MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Inagaki N; Kondo K; Yoshinari T; Takahashi N; Susuta Y; Kuki H
Expert Opin Pharmacother; 2014 Aug; 15(11):1501-15. PubMed ID: 25010793
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
16. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
17. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Schnell O
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S70-4. PubMed ID: 24481636
[No Abstract] [Full Text] [Related]
18. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S65-9. PubMed ID: 24481635
[No Abstract] [Full Text] [Related]
19. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N
South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]